Access to Pediatric Technologies Act of 2025
Summary
HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1931 is an early-stage bill with zero legislative progress in 13+ months; passage in the 119th Congress is unlikely
- 2.The bill creates a regulatory mechanism for Medicare reimbursement of pediatric technologies - it authorizes no direct spending
- 3.Impact on public med-tech and pharma companies (JNJ, ABT, MRK, PFE) is directionally positive but economically negligible given these companies' massive revenue bases
- 4.No real market price movement can be attributed to this bill - stock trends are driven by broader healthcare sector weakness
Market Implications
No immediate market implications. The bill is stuck in committee with no hearings scheduled. The 30-day price action for JNJ (-6.24%), ABT (-10.36%), MRK (-6.05%), and PFE (-5.44%) reflects broader sector selling, not legislative catalysts. Investors should treat this as a long-term policy signal that pediatric device/drug reimbursement is on Congress's radar, not a near-term trading catalyst. A committee hearing or markup would be the first actionable signal of momentum.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Establishes a direct CMS payment methodology under the Medicare physician fee schedule for qualifying pediatric technologies upon manufacturer request
Who must act
CMS must develop national relative value units for qualifying pediatric devices/drugs that are Medicare-covered, FDA-approved, and predominantly used for pediatric patients
What happens
Creates reimbursement certainty for pediatric device manufacturers, reducing financial risk of bringing pediatric-specific products to market under Medicare
Stock impact
ABT's medical device portfolio includes pediatric-focused products in nutrition, diagnostics, and vascular; the payment mechanism improves ROI on pediatric R&D, but pediatric device revenue is a niche within ABT's ~$40B total revenue
What the bill does
Establishes a direct CMS payment methodology under the Medicare physician fee schedule for qualifying pediatric technologies upon manufacturer request
Who must act
CMS must develop national relative value units for qualifying pediatric devices/drugs that are Medicare-covered, FDA-approved, and predominantly used for pediatric patients
What happens
Creates reimbursement certainty for pediatric drug manufacturers, reducing financial risk of developing pediatric indications for existing drugs or new pediatric formulations
Stock impact
MRK's pharmaceutical segment includes pediatric vaccines (e.g., Gardasil, MMR) and pediatric indications for drugs; the bill improves the business case for pediatric drug development by removing reimbursement uncertainty, but pediatric drug sales are a small portion of MRK's ~$60B revenue
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
American Innovation and R&D Competitiveness Act of 2025
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Lowering Drug Costs for American Families Act
Skinny Labels, Big Savings Act
Most Favored Patient Act of 2026
ABC Safe Drug Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.